# The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)

> **NCT04207944** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Duke University** · enrollment: 100 (estimated)

## Conditions studied

- IPMN
- IPMN, Pancreatic

## Interventions

- **DRUG:** Sulindac 400 MG
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04207944
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-10
- **Primary completion:** 2026-07-30
- **Final completion:** 2026-10-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04207944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04207944, "The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04207944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*